New obesity drug candidate monlunabant passes first safety check in healthy men

NCT ID NCT06542536

Completed Knowledge-focused Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 1 trial tested a single oral dose of monlunabant in 73 healthy Japanese and Caucasian men of normal weight. The main goal was to check safety and how the drug moves through the body. Participants received either monlunabant, placebo, or both, and were monitored for about 49 days. The study provides early safety data for this potential obesity treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: monlunabant
What this could lead to: If successful, this could support further development of monlunabant as a potential treatment for obesity.
What could go wrong: This is an early Phase 1 safety study in healthy men, not designed to test weight loss. Results may not predict effectiveness in people with obesity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OBESITY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY

Contacts and locations

Show contact details

Locations

Altasciences Clinical LA, Inc.

Cypress, California, 90630, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.